VTE with Amivantamab plus Chemotherapy in NSCLC. Reply

N Engl J Med. 2024 Feb 8;390(6):579-580. doi: 10.1056/NEJMc2314937.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Bispecific*
  • Carcinoma, Non-Small-Cell Lung* / complications
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors
  • Humans
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / drug therapy
  • Venous Thromboembolism* / drug therapy

Substances

  • amivantamab-vmjw
  • ErbB Receptors
  • EGFR protein, human
  • Antibodies, Bispecific